Parexel Achieves CDSCO Registration Milestone, Strengthens Presence in India
Mumbai, June 10th 2025: Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the successful completion of its Clinical Research Organization (CRO) registration with the Central Drugs Standard Control Organization (CDSCO). This registration complies with the new G.S.R 581 (E) regulation, which mandates all CROs operating in India to register with CDSCO.
Sanjay Vyas, President and Managing Director of Parexel India and Global Strategic Business Unit Head for Clinical Logistics & Global Safety Services, said, “This registration reflects our ongoing commitment to meeting regulatory requirements and upholding the highest standards in clinical research. This registration enables us to continue supporting our customers in bringing life-saving treatments to patients safely and efficiently.”
With over 40 years of global experience and a workforce of more than 6,000 in India, Parexel advances clinical research across complex therapeutic areas. Parexel acknowledges the dedication of its team in achieving this regulatory milestone and remains committed to driving innovation in India and globally, while continuing to uphold the highest standards of quality, compliance, and patient safety.
